Moderna and merck announce mrna-4157 (v940), an investigational individualized neoantigen therapy, in combination with keytruda(r) (pembrolizumab), demonstrated superior recurrence-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus keytruda

Mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 44% compared to keytruda alone in stage iii/iv melanoma patients with high risk of recurrence following complete resection results from the phase 2b keynote-942 trial selected for aacr press program companies will initiate a phase 3 study in patients with adjuvant melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer cambridge, ma and rahway, nj / accesswire / april 16, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside of the united states and canada, today announced the first presentation of detailed results from the phase 2b keynote-942/mrna-4157-p201 trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv). in the overall intention-to-treat population, adjuvant treatment with mrna-4157 (v940) in combination with keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (rfs), and reduced the risk of recurrence or death by 44% (hr=0.56 [95% ci, 0.309-1.017]; one-sided p value=0.0266) compared with keytruda alone.
MRNA Ratings Summary
MRNA Quant Ranking